Pancreatic Cancer Research

ResearcherNebraska Medical CenterActive in the last 2 years

Moorthy Palanimuthu Ponnusamy

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5744-193X; OpenAlex author ID A5023967002; NIH RePORTER profile ID 10207340. Sources: OpenAlex.

Their work

Papers
55 (first author 6, last author 17)
Trials
0
Grants
3
Labs led
1
Collaborators
96
Papers, trials and grants by year

2011: 3 papers · 2012: 3 papers · 2013: 2 papers · 2014: 2 papers · 2015: 3 papers · 2016: 7 papers, 1 grant · 2017: none · 2018: 3 papers · 2019: 1 paper · 2020: 2 papers · 2021: 6 papers, 1 grant · 2022: 9 papers · 2023: 2 papers · 2024: 5 papers · 2025: 2 papers, 1 grant · 2026: 5 papers

Papers 50 of 55

  1. The underexplored complexity of pancreatic cancer: Early dissemination and quiescence. Last author DOI 10.1016/j.bbcan.2026.189606↗
  2. Targeting the DDX3/PAF1 axis enhances chemotherapy efficacy in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.canlet.2026.218276↗
  3. SLC22A3/OCT3 drives serotonin-mediated stemness in pancreatic cancer. Last author DOI 10.1016/j.celrep.2026.117387↗
  4. Distinct glycosyltransferase expression governs organ-specific survival in pancreatic cancer metastasis. Last author DOI 10.1038/s41388-026-03896-5↗
  5. Unveiling the gut-pancreas axis: microbial influence on stemness and tumor microenvironment of PDAC. Last author DOI 10.1093/stmcls/sxaf064↗
  6. Targeting cancer-associated fibroblast-driven LIF/LIFR axis improves the therapeutic efficacy of gemcitabine and nab-paclitaxel in pancreatic cancer. Co-author DOI 10.1038/s41698-025-01046-w↗
  7. Emerging pathways yielding opportunities for future treatments in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/14728222.2025.2507035↗
  8. Secretory Trefoil Factor 1 (TFF1) promotes gemcitabine resistance through chemokine receptor CXCR4 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.canlet.2024.217097↗
  9. Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.drup.2024.101146↗
  10. Connectivity mapping-based identification of pharmacological inhibitor targeting HDAC6 in aggressive pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-024-00562-5↗
  11. Cancer-Associated Fibroblast Induces Acinar-to-Ductal Cell Transdifferentiation and Pancreatic Cancer Initiation Via LAMA5/ITGA4 Axis. Last author DOI 10.1053/j.gastro.2023.12.018↗
  12. PAF1/HIF1α axis rewires the glycolytic metabolism to fuel aggressiveness of pancreatic cancer. Last author DOI 10.1186/s40170-024-00354-2↗
  13. Metabolic Rewiring and Stemness: A Critical Attribute of Pancreatic Cancer Progression. Last author DOI 10.1093/stmcls/sxad017↗
  14. MUC16 and TP53 family co-regulate tumor-stromal heterogeneity in pancreatic adenocarcinoma. Co-author DOI 10.3389/fonc.2023.1073820↗
  15. Acinar to ductal cell trans-differentiation: A prelude to dysplasia and pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.bbcan.2021.188669↗
  16. Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2022.215922↗
  17. Disruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling. Co-author DOI 10.1016/j.ebiom.2021.103772↗
  18. Chemokine-mucinome interplay in shaping the heterogeneous tumor microenvironment of pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2022.03.022↗
  19. Reduction in O-glycome induces differentially glycosylated CD44 to promote stemness and metastasis in pancreatic cancer. Last author DOI 10.1038/s41388-021-02047-2↗
  20. Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-022-02493-6↗
  21. PAF1 cooperates with YAP1 in metaplastic ducts to promote pancreatic cancer. Last author DOI 10.1038/s41419-022-05258-x↗
  22. A p130Cas-Mediated Mechanism Governs Acinar to Ductal Metaplasia and the Initiation of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1053/j.gastro.2022.01.042↗
  23. MUC16 Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma by Upregulating NRP2-Associated Cell Adhesion. Co-author DOI 10.1158/1541-7786.mcr-21-0888↗
  24. Nanoscale platform for delivery of active IRINOX to combat pancreatic cancer. Co-author DOI 10.1016/j.jconrel.2020.11.029↗
  25. Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41388-020-01518-2↗
  26. Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis. Co-author DOI 10.1038/s41388-020-01564-w↗
  27. MASTL regulates EGFR signaling to impact pancreatic cancer progression. Co-author DOI 10.1038/s41388-021-01951-x↗
  28. SUMO Modification of PAF1/PD2 Enables PML Interaction and Promotes Radiation Resistance in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1128/mcb.00135-21↗
  29. Secretory Mucin 5AC Promotes Neoplastic Progression by Augmenting KLF4-Mediated Pancreatic Cancer Cell Stemness. Co-author DOI 10.1158/0008-5472.can-20-1293↗
  30. Global analysis of human glycosyltransferases reveals novel targets for pancreatic cancer pathogenesis. Last author DOI 10.1038/s41416-020-0772-3↗
  31. RNA Polymerase II-Associated Factor 1 Regulates Stem Cell Features of Pancreatic Cancer Cells, Independently of the PAF1 Complex, via Interactions With PHF5A a… Co-author DOI 10.1053/j.gastro.2020.07.053↗
  32. MicroRNA regulation of K-Ras in pancreatic cancer and opportunities for therapeutic intervention. Co-author DOI 10.1016/j.semcancer.2017.11.020↗
  33. Cigarette Smoke Induces Stem Cell Features of Pancreatic Cancer Cells via PAF1. Last author DOI 10.1053/j.gastro.2018.05.041↗
  34. Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. Co-author DOI 10.1080/15384047.2017.1416937↗
  35. Novel role of O-glycosyltransferases GALNT3 and B3GNT3 in the self-renewal of pancreatic cancer stem cells. Last author DOI 10.1186/s12885-018-5074-2↗
  36. The canonical Wnt pathway regulates the metastasis-promoting mucin MUC4 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.molonc.2015.10.005↗
  37. Bile acids-mediated overexpression of MUC4 via FAK-dependent c-Jun activation in pancreatic cancer. Co-author DOI 10.1016/j.molonc.2016.04.007↗
  38. Loss of N-acetylgalactosaminyltransferase 3 in poorly differentiated pancreatic cancer: augmented aggressiveness and aberrant ErbB family glycosylation. Co-author DOI 10.1038/bjc.2016.116↗
  39. Hypoxia-induced oxidative stress promotes MUC4 degradation via autophagy to enhance pancreatic cancer cells survival. Co-author DOI 10.1038/onc.2016.119↗
  40. PR55α Subunit of Protein Phosphatase 2A Supports the Tumorigenic and Metastatic Potential of Pancreatic Cancer Cells by Sustaining Hyperactive Oncogenic Signal… Co-author DOI 10.1158/0008-5472.can-15-2119↗
  41. MUC16 contributes to the metastasis of pancreatic ductal adenocarcinoma through focal adhesion mediated signaling mechanism. Co-author DOI 10.18632/genesandcancer.104↗
  42. Overexpression of PD2 leads to increased tumorigenicity and metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.6580↗
  43. NCOA3-mediated upregulation of mucin expression via transcriptional and post-translational changes during the development of pancreatic cancer. Co-author DOI 10.1038/onc.2014.409↗
  44. Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer. First author DOI 10.18632/oncotarget.3286↗
  45. Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.3912↗
  46. Novel role of pancreatic differentiation 2 in facilitating self-renewal and drug resistance of pancreatic cancer stem cells. First author DOI 10.1038/bjc.2014.152↗
  47. A concise review on the current understanding of pancreatic cancer stem cells. First author DOI 10.14343/jcscr.2014.2e1004↗
  48. Guggulsterone decreases proliferation and metastatic behavior of pancreatic cancer cells by modulating JAK/STAT and Src/FAK signaling. Co-author DOI 10.1016/j.canlet.2013.07.037↗
  49. Nicotine/cigarette smoke promotes metastasis of pancreatic cancer through α7nAChR-mediated MUC4 upregulation. First author DOI 10.1038/onc.2012.163↗
  50. MUC4 potentiates invasion and metastasis of pancreatic cancer cells through stabilization of fibroblast growth factor receptor 1. Co-author DOI 10.1093/carcin/bgs225↗

Grants 3

  1. Truncated O-glycan-dependent mechanisms inducing metastatic dissemination in pancreatic cancer R01CA273349↗
  2. Role of PD2/Paf1 in Pancreatic Acinar to Ductal Metaplasia R01CA210637↗
  3. PD2/Paf1 and pancreatic cancer stem cells K22CA175260↗

Closest collaborators

The 25 strongest of 96 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Surinder K. Batra · 54 shared papers, 2 shared grants, 2011–2026 · strength 8.73
  2. Sanchita Rauth · 20 shared papers, 2018–2026 · strength 2.96
  3. Rama Krishna Nimmakayala · 19 shared papers, 2018–2024 · strength 2.73
  4. Satyanarayana Rachagani · 28 shared papers, 2011–2024 · strength 2.22
  5. Ashu Shah · 12 shared papers, 2021–2026 · strength 2.19
  6. Palanisamy Nallasamy · 13 shared papers, 2020–2026 · strength 1.99
  7. Parthasarathy Seshacharyulu · 18 shared papers, 2012–2026 · strength 1.93
  8. Jesse L. Cox · 10 shared papers, 2021–2026 · strength 1.72
  9. Zahraa Wajih Alsafwani · 7 shared papers, 2023–2026 · strength 1.49
  10. Maneesh Jain · 14 shared papers, 2011–2025 · strength 1.45
  11. Pranita Atri · 9 shared papers, 2018–2024 · strength 1.19
  12. Sushil Kumar K · 12 shared papers, 2011–2024 · strength 1.16
  13. Saravanakumar Marimuthu · 7 shared papers, 2021–2026 · strength 1.16
  14. Lynette M. Smith · 12 shared papers, 2011–2024 · strength 1.12
  15. Kavita B. Mallya · 7 shared papers, 2021–2026 · strength 1.06
  16. Nivedeta Krishna Kumar · 4 shared papers, 2022–2026 · strength 1.01
  17. Seema C. Parte · 6 shared papers, 2022–2024 · strength 1.00
  18. Geoffrey A. Talmon · 7 shared papers, 2018–2026 · strength 0.99
  19. Kirtana Arikath · 3 shared papers, 2026 · strength 0.95
  20. Subodh M. Lele · 8 shared papers, 2011–2026 · strength 0.92
  21. Venkatesh Varadharaj · 4 shared papers, 2022–2026 · strength 0.85
  22. Frank Leon · 6 shared papers, 2020–2026 · strength 0.84
  23. Ayoola O. Ogunleye · 4 shared papers, 2022–2024 · strength 0.80
  24. Koelina Ganguly · 5 shared papers, 2021–2024 · strength 0.78
  25. Saswati Karmakar · 8 shared papers, 2016–2022 · strength 0.78

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.